PR Newswire - Transcenta Updates Encouraging Efficacy Data from ...
Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and SUZHOU,...
Read More

ภาษาไทย
English